# Xeris Biopharma Holdings, Inc. (XERS): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for Xeris Biopharma Holdings, Inc. (XERS) is 55/100, ranked against 24,000+ stocks in 35 markets (Quality 59, Value 26, Momentum 65, each scored against its sector).

- StockRank: 55/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 59, Value 26, Momentum 65: each a 0-100 percentile within Healthcare.
- Position: #11,778 overall, #1,102 in Healthcare.
- Listing: United States, NMS; Healthcare / Drug Manufacturers - Specialty & Generic.
- Last close: 10.21 USD on 26 Oct 2026.
- Insider filings, last 180 days: directors sold USD 3.0M.

Source: https://moatmap.ai/stock/XERS
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker